W. A. Craig

1.1k total citations
17 papers, 894 citations indexed

About

W. A. Craig is a scholar working on Pharmacology, Molecular Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, W. A. Craig has authored 17 papers receiving a total of 894 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 8 papers in Molecular Medicine and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in W. A. Craig's work include Antibiotics Pharmacokinetics and Efficacy (10 papers), Antibiotic Resistance in Bacteria (8 papers) and Pharmaceutical studies and practices (4 papers). W. A. Craig is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (10 papers), Antibiotic Resistance in Bacteria (8 papers) and Pharmaceutical studies and practices (4 papers). W. A. Craig collaborates with scholars based in United States and Canada. W. A. Craig's co-authors include Steven C. Ebert, J. E. Leggett, Peter G. Welling, B. Fantin, C. M. Kunin, Andreas Gerber, A. Paul Vastola, Byungse Suh, William Kirby and Paul G. Ambrose and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

W. A. Craig

17 papers receiving 822 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. A. Craig United States 14 576 395 273 213 180 17 894
H. A. Holt United Kingdom 21 720 1.3× 568 1.4× 397 1.5× 229 1.1× 180 1.0× 54 1.2k
C H Nightingale United States 17 657 1.1× 325 0.8× 427 1.6× 192 0.9× 115 0.6× 37 1.0k
C Regamey Switzerland 19 718 1.2× 300 0.8× 401 1.5× 276 1.3× 139 0.8× 56 1.3k
H. Lode Germany 17 619 1.1× 407 1.0× 545 2.0× 256 1.2× 160 0.9× 47 1.4k
P Labthavikul United States 22 653 1.1× 512 1.3× 350 1.3× 280 1.3× 140 0.8× 35 1.3k
L. O. White United Kingdom 18 426 0.7× 217 0.5× 209 0.8× 100 0.5× 85 0.5× 33 749
Thomas J. Cumbo United States 13 464 0.8× 214 0.5× 291 1.1× 210 1.0× 141 0.8× 21 891
Jan G. den Hollander Netherlands 16 477 0.8× 371 0.9× 473 1.7× 289 1.4× 80 0.4× 32 1.2k
K. A. Bedford United Kingdom 13 448 0.8× 328 0.8× 174 0.6× 111 0.5× 52 0.3× 22 672
Thomas R. Beam United States 17 247 0.4× 166 0.4× 401 1.5× 167 0.8× 120 0.7× 45 869

Countries citing papers authored by W. A. Craig

Since Specialization
Citations

This map shows the geographic impact of W. A. Craig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. A. Craig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. A. Craig more than expected).

Fields of papers citing papers by W. A. Craig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. A. Craig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. A. Craig. The network helps show where W. A. Craig may publish in the future.

Co-authorship network of co-authors of W. A. Craig

This figure shows the co-authorship network connecting the top 25 collaborators of W. A. Craig. A scholar is included among the top collaborators of W. A. Craig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. A. Craig. W. A. Craig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ambrose, Paul G., George L. Drusano, & W. A. Craig. (2012). In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in Humans. Clinical Infectious Diseases. 54(suppl 3). S220–S228. 48 indexed citations
2.
Finberg, Robert W., Robert C. Moellering, Francis P. Tally, et al.. (2004). The Importance of Bactericidal Drugs: Future Directions in Infectious Disease. Clinical Infectious Diseases. 39(9). 1314–1320. 151 indexed citations
3.
Craig, W. A., Sungmin Kiem, & David R. Andes. (2002). Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin. 42. 14. 21 indexed citations
4.
Vesga, Ómar, et al.. (1996). Pharmacodynamic activity of BAY 12-8039 in animal infection models. 36. 103. 3 indexed citations
5.
Craig, W. A., et al.. (1991). Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. Journal of Antimicrobial Chemotherapy. 27(suppl C). 29–40. 192 indexed citations
6.
Leggett, J. E., Steven C. Ebert, B. Fantin, & W. A. Craig. (1990). Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models.. PubMed. 74. 179–84. 109 indexed citations
7.
Leggett, J. E. & W. A. Craig. (1989). Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrobial Agents and Chemotherapy. 33(1). 35–40. 39 indexed citations
8.
Kunin, C. M., David N. Gilbert, Allan Ronald, et al.. (1987). Report from the Antimicrobial Agents Committee. The Journal of Infectious Diseases. 156(5). 700–705. 9 indexed citations
9.
Welling, Peter G., et al.. (1983). Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrobial Agents and Chemotherapy. 23(6). 881–887. 25 indexed citations
10.
Gerber, Andreas, et al.. (1982). Selection of Aminoglycoside-Resistant Variants of Pseudomonas aeruginosa in an in Vivo Model. The Journal of Infectious Diseases. 146(5). 691–697. 89 indexed citations
11.
Toothaker, Roger D., et al.. (1981). Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays. Antimicrobial Agents and Chemotherapy. 19(3). 443–449. 36 indexed citations
12.
Kirby, William & W. A. Craig. (1981). Theory and Applications of Pulse Dosing: A Summary of the Symposium. Clinical Infectious Diseases. 3(1). 1–3. 31 indexed citations
13.
Craig, W. A. & Andreas Gerber. (1981). Worldwide Experience with Bacampicillin Administered Twice a Day. Clinical Infectious Diseases. 3(1). 171–177. 3 indexed citations
14.
Craig, W. A., et al.. (1978). Changes in protein binding during disease.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 239–44. 15 indexed citations
15.
Craig, W. A. & Byungse Suh. (1978). Theory and practical impact of binding of antimicrobials to serum proteins and tissue.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 92–9. 33 indexed citations
16.
Welling, Peter G., W. A. Craig, & C. M. Kunin. (1975). Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clinical Pharmacology & Therapeutics. 18(1). 45–52. 32 indexed citations
17.
Craig, W. A., Peter G. Welling, Thomas C. Jackson, & C. M. Kunin. (1973). Pharmacology of Cefazolin and Other Cephalosporins in Patients with Renal Insufficiency. The Journal of Infectious Diseases. 128(Supplement 2). S347–S353. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026